Developing novel, immune-based therapies for medically unmet, life-threatening and life-limiting diseases

NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology

Oct 5, 2021

Highlights potential of novel antifungal’s immune-based approach to inhibit fungal pathogens Aberdeen, October 5, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases,...

NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology

NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF)

This new data further supports the potential of NM001 against the most clinically challenging bacterial pathogens, including Pseudomonas aeruginosa, in respiratory disease. NM001 is a registration study-ready candidate intervention (acute use) for pulmonary...

NovaBiotics Highlights Advantages of Novel Immune-Based Approach to Combatting Fungal and Bacterial Infectious Diseases at Peptide Therapeutics Forum 2021

Aberdeen, August 24, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases, announces that Deborah O’Neil, Ph.D., Chief Executive Officer of NovaBiotics, delivered...

NovaBiotics Announces Presentation at Upcoming Peptide Therapeutics Forum 2021

Highlights proprietary peptide platform and immune-based approach with manifold therapeutic advantages over traditional drug classes to combat life-threatening fungal and bacterial infectious diseases Aberdeen, August 2, 2021. NovaBiotics Ltd, a privately held...

NovaBiotics Named as One of Scotland’s Top Ten Biotech Companies to Watch Out For

NovaBiotics were highlighted in Jonathan Smith’s article in Labiotech on “Scotland’s Top Ten Biotech Companies to Watch Out For.” Learn more about Scotland's “thriving life sciences ecosystem” by accessing the article Labiotech Article Scotland's Top Ten Biotech...

NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia

Randomized embedded multi-factorial platform trial to provide accelerated, real-world evidence in community acquired pneumonias including COVID-19, influenzas and bacterial pneumonias Aberdeen, June 21, 2021. NovaBiotics Ltd, a privately held clinical stage company...

NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy

Peer reviewed journal article highlights Company’s novel antifungal peptide’s activity against a broad range of fungal pathogens with no off target cytotoxicity Aberdeen, June 1, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune...

NovaBiotics attending the BIO Digital Meeting, June 2021

NovaBiotics are looking forward to participating at the upcoming BIO Digital Meeting taking place on June 10-11 & 14-18, 2021. The team are ready to meet with all interested parties and explain how we are using immunology to deliver novel therapies for...

Clear and unbiased facts about why the COVID 19/Pneumonia relationship is bad news

By Grant Ellis, Director, NovaBiotics Ltd A number of commentators are now saying that as a result of the vaccines, COVID 19 will be akin to flu – something that comes around every year but for most of us nothing more than an inconvenience and only severely...

Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics

Aberdeen, UK – 26th February 2021 – NovaBiotics Ltd, the clinical-stage anti-infectives biotechnology company, today announced that it has entered into a licensing agreement with an undisclosed partner to commercialise its NP213 peptide in a topical (brush/paint-on)...

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on leveraging its novel immunology platforms to design and develop first-in-class therapies to address difficult-to-treat, medically unmet diseases.

The Company’s advanced portfolio of therapeutic candidates target life-threatening and life-limiting diseases in the inflammation, infection and respiratory space.

NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to initiation of phase 3 clinical trials of its portfolio of therapeutic candidates. These first in class molecules have been developed from NovaBiotics’ two proprietary Technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.